JCO oncology practice最新文献

{"title":"Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01).","authors":"Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, Jeannette Y Lee, Yuelin Li, Kathleen A Lynch, Andrew Webb, Susan M Holland, Erica I Lubetkin, Stephen Goldstone, Mark H Einstein, Elizabeth A Stier, Dorothy J Wiley, Ronald Mitsuyasu, Isabella Rosa-Cunha, David M Aboulafia, Shireesha Dhanireddy, Jeffrey T Schouten, Rebecca Levine, Edward M Gardner, Hillary Dunlevy, Luis F Barroso, Gary Bucher, Jessica Korman, Benjamin Stearn, Timothy J Wilkin, Grant Ellsworth, Julia C Pugliese, David Cella, J Michael Berry-Lawhorn, Joel M Palefsky","doi":"10.1200/OP-24-00830","DOIUrl":"https://doi.org/10.1200/OP-24-00830","url":null,"abstract":"<p><strong>Purpose: </strong>The Anal Cancer/High-grade squamous intraepithelial lesions Outcomes Research (ANCHOR) trial demonstrated that treating precancerous anal HSIL reduces the incidence of anal cancer by 57% in people with HIV. It remains unclear how HSIL treatment or monitoring without treatment affects patient-reported health-related quality of life (HRQoL). We evaluated differences in HRQoL for individuals who were randomly assigned to active monitoring (AM) or treatment for anal HSIL.</p><p><strong>Methods: </strong>Using an index designed and validated for use in ANCHOR, HRQoL was assessed before random assignment (T1), 2-7 days (+3 days) after random assignment/treatment (T2), and 28 days (±7 days) after random assignment/treatment (T3).</p><p><strong>Results: </strong>ANCHOR participants living with HIV (N = 124; mean [standard deviation, SD] age, 52.6 years [10.3]; n = 101 [81.5%] men; n = 65 [52.4%] White; n = 95 [76.6%] non-Hispanic; treatment n = 70 [56.4%]; and AM n = 54 [43.6%]) were included. Treatment arm participants had significant mean worsening from T1-T2 in physical symptoms (mean [SD] difference, 0.31 [0.51]; <i>P</i> = .0001) and impact on psychological functioning (mean [SD] difference, 0.25 [0.64]; <i>P</i> = .022) that significantly improved to T1 levels from T2-T3 (ie, mean [SD] difference, -0.25 [0.52]; <i>P</i> = .003; and mean [SD] difference, -0.07 [0.23]; <i>P</i> = .039, respectively). AM arm participants experienced significant mean improvement in impact on psychological functioning from T1-T3 (mean [SD], difference, -0.20 [0.50]; <i>P</i> = .017). After adjusting for T1, treatment arm participants had a larger mean improvement than AM arm participants in physical symptoms from T2-T3 (mean [SD] difference, -0.25 [0.52]; <i>P</i> = .024); no between-arm differences were observed for impact on physical or psychological functioning.</p><p><strong>Conclusion: </strong>Treatment arm participants experienced significant worsening in physical symptoms and impact on psychological functioning from T1-T2 but returned to prerandomization levels by T3, indicating that any immediate anal HSIL treatment-related impacts to HRQoL are temporary. Further research is needed to determine long-term impacts of anal HSIL treatment on HRQoL.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400830"},"PeriodicalIF":4.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Developments in the Management of Renal Cell Cancer.","authors":"Yu-Wei Chen, Justine Panian, Brent Rose, Aditya Bagrodia, Rana R McKay","doi":"10.1200/OP-24-00875","DOIUrl":"https://doi.org/10.1200/OP-24-00875","url":null,"abstract":"<p><p>The management of renal cell carcinoma (RCC) has seen significant advancements in recent years with the introduction of novel therapeutic agents and combination regimens. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape, particularly for advanced and metastatic RCC, where ICI-based combinations have shown substantial improvements in survival outcomes. Dual immunotherapy combinations, such as nivolumab plus ipilimumab, and ICI-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) combinations, including pembrolizumab with axitinib, nivolumab with cabozantinib, and pembrolizumab with lenvatinib, have demonstrated overall survival (OS) benefits in first-line treatment, redefining the standard of care for advanced RCC. Adjuvant pembrolizumab is also approved for resected high-risk RCC and is the only adjuvant therapy that prolongs the OS in RCC. Additionally, the development of belzutifan, a hypoxia-inducible factor-2 alpha inhibitor, offers a new treatment option for patients whose disease progresses after ICI and VEGF TKI therapies. Recent results from CONTACT-3 and TiNiVo-2 confirm that ICI rechallenge should be generally discouraged. This review provides a detailed overview of the current evidence supporting immune-based combinations and novel agents such as belzutifan, as well as insights into treatment sequencing strategies for RCC.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400875"},"PeriodicalIF":4.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participation in Electronic Patient-Reported Outcome Measures Collection as a Part of Routine Supportive Care Delivery in Oncology.","authors":"SriVarsha Katoju, Oliver T Nguyen, Sahana Rajasekhara, Young-Rock Hong, Amir Alishahi Tabriz, Kea Turner","doi":"10.1200/OP-24-00760","DOIUrl":"https://doi.org/10.1200/OP-24-00760","url":null,"abstract":"<p><strong>Purpose: </strong>The use of electronic patient-reported outcome measures (ePROMs) in supportive cancer care can lead to benefits, such as identifying at-risk patients in need of closer monitoring and treatment. Despite these benefits, most studies examining ePROMs in this area were for clinical trials rather than standard care. Since there is a need to identify which patients are more likely to participate in ePROMs, this study assessed ePROM participation rates and factors influencing greater participation among patients receiving supportive care.</p><p><strong>Methods: </strong>This retrospective data analysis took place at a supportive care clinic within a National Cancer Institute-designated Comprehensive Cancer Center in the southeastern United States. Starting in 2017, ePROM assessments were implemented using tablets for in-person appointments at the clinic. The assessments included the Patient Health Questionnaire-9, National Comprehensive Cancer Network Distress Thermometer, and Edmonton Symptom Assessment System with additional questions added for other symptoms. Logistic regression and zero-truncated negative binomial regression models were used to analyze factors associated with ePROM assessment submission.</p><p><strong>Results: </strong>The study included 4,780 patients, with 42.7% submitting at least one ePROM assessment. Higher odds of ePROM submission were observed among patients age 35-64 years, had Medicare, had nonmetastatic cancer, or had genitourinary, breast, or multiple cancers. Additionally, higher rates of ePROM submissions were observed among patients who were younger; had GI, breast, or multiple cancers; had nonmetastatic cancer; or had private insurance.</p><p><strong>Conclusion: </strong>This study reveals that submission rates of ePROM assessments in a cancer center's supportive care clinic may be influenced by patient demographics, cancer history, and social determinants of health. Interventions to improve ePROM submission rates may need to be tailored on the basis of cancer site, presence of metastatic cancer, and caregiver support.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400760"},"PeriodicalIF":4.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists.","authors":"Yu Zhang, Shelli R Kesler, Jorg Dietrich, Herta H Chao","doi":"10.1200/OP-24-00953","DOIUrl":"https://doi.org/10.1200/OP-24-00953","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400953"},"PeriodicalIF":4.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment.","authors":"Veronica Mears, Nikolas Naleid, Omkar Pawar, Jennifer Eva Selfridge, Madison Conces, Melissa Lumish, David Bajor, Amit Mahipal, Sakti Chakrabarti","doi":"10.1200/OP-24-00647","DOIUrl":"https://doi.org/10.1200/OP-24-00647","url":null,"abstract":"<p><strong>Purpose: </strong>The combination of capecitabine and oxaliplatin (CAPOX) is commonly used in patients with localized colorectal cancer (CRC) receiving curative-intent treatment. Our study aimed to assess the real-world tolerability of CAPOX in a single-institution cohort of patients with localized CRC.</p><p><strong>Methods: </strong>This is a single-institution retrospective study that included patients with localized CRC receiving neoadjuvant or adjuvant CAPOX. The primary end point was completion rate of intended number (obtained by chart review) of CAPOX cycles irrespective of dose levels. Secondary outcome measures included the rate of grade ≥3 adverse events, hospital admission rate, and dose reductions.</p><p><strong>Results: </strong>The study included 153 patients with a median age of 61 years; 49% were female and 78.4% had stage III CRC. The proportion of patients (95% CI) who completed all planned CAPOX cycles was 44.4% (36 to 52) in the entire cohort and 34.6% (23 to 45) among female patients. Independent variables associated with treatment completion in multivariable analysis were race, sex, and intended number of cycles. Notably, the therapy completion rates (95% CI) were 55% (43 to 66) and 33% (20 to 45) in patients intended to receive four and eight cycles of CAPOX, respectively. The rate of grade ≥3 adverse events and hospitalization because of CAPOX-related toxicity were 30.7% (95% CI, 23 to 38) and 17.6% (95% CI, 11 to 23), respectively.</p><p><strong>Conclusion: </strong>This study highlights that a substantial number of patients with localized CRC undergoing curative-intent treatment with CAPOX do not complete the planned cycles of chemotherapy because of toxicity. These findings underscore the need for careful patient selection and appropriate supportive care to optimize the therapeutic benefit of CAPOX in this setting.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400647"},"PeriodicalIF":4.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Associated Factors for Depression Among Patients With Sarcoma.","authors":"Michael J Robinson, Sang Minh Nguyen, Debra L Friedman, Emma A Schremp, Lucy L Wang, Scott C Borinstein, Elizabeth J Davis, Tuya Pal, Ben H Park, Xiao-Ou Shu","doi":"10.1200/OP.24.00163","DOIUrl":"https://doi.org/10.1200/OP.24.00163","url":null,"abstract":"<p><strong>Purpose: </strong>Prevalence and risk factors for depression among patients with sarcoma and survivors of sarcoma are not well characterized.</p><p><strong>Methods: </strong>A sarcoma survivorship cohort was constructed from patients diagnosed between April 2022 and September 2023. Depression symptoms were assessed via the eight-item Patient-Reported Outcomes Measurement Information System-57 depression scale at enrollment. Standardized <i>T</i>-score levels (<50, 50-59, and ≥60) were calculated and evaluated in association with demographics, lifestyle characteristics, clinical data, and modifiable factors using multinomial logistic regression models.</p><p><strong>Results: </strong>Among 612 participants, the mean <i>T</i>-score was 48.3 (standard deviation, 10.0); 58.8% had a <i>T</i>-score <50, 27.9% scored between 50 and 59, and 13.2% scored ≥60. Participants age 18-39 years and age 40-59 years were more likely to have a <i>T</i>-score ≥60, with respective odds ratios (ORs) of 3.65 (95% CIs, 1.70 to 7.83) and 2.80 (1.52 to 5.17) compared with participants older than 60 years. Household incomes of $70,000-$120,000 in US dollars (USD) (OR, 0.46 [95% CI, 0.23 to 0.92]) and >$120,000 USD (OR, 0.15 [95% CI, 0.06 to 0.37]) were inversely associated with <i>T</i>-score ≥60 compared with household incomes <$45,000 USD. Marijuana use within the past 30 days was positively (OR, 3.48 [95% CI, 1.46 to 8.27]) associated, while regular exercise (OR, 0.43 [95% CI, 0.24 to 0.75]) and emotional support (OR, 0.37 [95% CI, 0.28 to 0.48]) were inversely associated with having <i>T</i>-score ≥60.</p><p><strong>Conclusion: </strong>A higher prevalence of depression symptoms was notable in younger participants, marijuana users, and households with lower incomes. Regular exercise and increased emotional support were inversely associated with depression symptoms. Our study provides information for developing personalized supportive care strategies to ameliorate depression symptoms among patients with sarcoma.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400163"},"PeriodicalIF":4.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Germline Hereditary Cancer Gene Panel Testing by Nongenetics Providers: 3-Year Experience in Large Integrated Health Care Delivery System.","authors":"Trevor L Hoffman, Farah M Brasfield, Devansu Tewari, Jeffery D Greenberg, Hilary B Kershberg, John Goff, Reina Haque, Monica Alvarado","doi":"10.1200/OP-24-00717","DOIUrl":"https://doi.org/10.1200/OP-24-00717","url":null,"abstract":"<p><strong>Purpose: </strong>Demand for germline hereditary cancer genetic testing has increased because of reduced cost, gene discovery, expanding indications, and precision cancer therapies. The traditional model for germline testing, where a genetics provider performs all steps of the testing process (pretest counseling, test ordering, results disclosure, and post-test counseling), is no longer able to meet testing needs especially for patients with cancer needing timely germline testing for treatment decisions. Mainstreaming has emerged as an alternative approach to increase testing capacity and efficiency, where nongenetics providers perform these steps and genetics providers focus on post-test counseling for positive results.</p><p><strong>Methods: </strong>This study reports a 3-year experience with mainstreaming hereditary cancer gene panel testing at Kaiser Permanente Southern California. The study compared demographic characteristics, cancer diagnoses, and test results between patients tested by genetics providers (traditional model) versus nongenetics providers (mainstreaming) over 3 years. Over 32,000 germline hereditary cancer gene panels were completed, including nearly 12,000 mainstreaming tests.</p><p><strong>Results: </strong>Mainstreaming substantially increased testing volume. Patients undergoing mainstream testing were more likely to have cancer, be male, and self-report being Asian or Black. The positive test rate was slightly lower in the mainstreaming group (11%) compared with the traditional testing model (15%), with similar rates of variants of uncertain significance. Post-test genetic counseling was high in both groups for positive results.</p><p><strong>Conclusion: </strong>This study demonstrates that mainstreaming can be successfully implemented in a large health care system and significantly expand testing capacity.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400717"},"PeriodicalIF":4.7,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022.","authors":"Sofie Seghers, Pablo Mandó, Marc Eid, Charles J Tan, Aarthi Jayraj, Karan Jatwani, Muhammad Salman Faisal, Vi Luong, Joanna A Young, Laure-Anne Teuwen, Hans Prenen, Eva Segelov","doi":"10.1200/OP-24-00739","DOIUrl":"https://doi.org/10.1200/OP-24-00739","url":null,"abstract":"<p><strong>Purpose: </strong>The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the ASCO Value Framework (ASCO-VF) are tools designed to assess the value of anticancer therapies. International conferences are the primary venues for sharing trial outcomes, often influencing clinical practices even before full publications are available. This analysis compares the ESMO-MCBS and ASCO-VF in evaluating the benefit of all phase III trials presented at the 2022 ASCO Annual Meeting (AM) and to examine the level of agreement between these scales.</p><p><strong>Methods: </strong>A systematic search of abstracts from the 2022 ASCO AM was conducted, focusing on phase III trial data presented. The clinical benefit of each abstract was assessed using both ESMO-MCBS and ASCO-VF, and Cohen's κ coefficients were calculated to analyze concordance between the tools.</p><p><strong>Results: </strong>Out of 239 phase III trial abstracts, 90 trials involving 49,721 patients met the inclusion criteria. Of these, 36 (40%) could not be graded by ESMO-MCBS, mainly because of nonsignificant results. Among the 54 gradable abstracts, 61.1% (n = 33) were deemed to provide substantial clinical benefit. ASCO-VF was unable to grade 40 (44.4%) abstracts, with nonsignificant results being the leading cause. Of the 50 gradable abstracts, 20% (n = 10) were considered to offer substantial clinical benefit. Moderate agreement between ESMO-MCBS and ASCO-VF was observed (Cohen's kappa, 0.4783 [95% CI, 0.3673 to 0.6034]). No significant association was found between clinical benefit and research funding or the economic status of the trial's origin country.</p><p><strong>Conclusion: </strong>Both frameworks showed a high rate of nongradable studies, primarily because of nonsignificant results. ESMO-MCBS identified more studies with substantial clinical benefit, and the agreement between the two tools was moderate.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2400739"},"PeriodicalIF":4.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in the Management of Advanced Prostate Cancer.","authors":"Zeynep Irem Ozay, Umang Swami, Neeraj Agarwal","doi":"10.1200/OP-25-00037","DOIUrl":"https://doi.org/10.1200/OP-25-00037","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500037"},"PeriodicalIF":4.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial.","authors":"Ilana Graetz, Samuel Hernandez, Sara Arshad, Kristina Byers, Jane Meisel, Gelareh Sadigh, Elizabeth A Sakach, Keerthi Gogineni, Mylin A Torres","doi":"10.1200/OP-25-00096","DOIUrl":"https://doi.org/10.1200/OP-25-00096","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2500096"},"PeriodicalIF":4.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}